UKRI’s MRC awards £27.4m to University of Dundee research unit
The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension
Read More
Tag: Parkinson’s
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
